Consensus Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
390.6 USD -0.01% Intraday chart for Medpace Holdings, Inc. -0.70% +27.41%

Evolution of the average Target Price on Medpace Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d1b69edf3bec0920.j7P-GS2wkMlDsIRtKhhFD0fvcWXvU-V7qwskv4sRbyI.6sC1c0_K-6x0g-McYXU3aH-DBDeFOoIkxGNt7711JUu92olaGOncnQDy4w~95da5ba89dd97aaeeb2fd7e547b48a60
Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating MT
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450 MT
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating MT
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282 MT
UBS Adjusts Medpace Price Target to $282 From $270, Maintains Neutral Rating MT
Baird Upgrades Medpace Holdings to Outperform From Neutral, Adjusts Price Target to $289 From $270 MT
UBS Adjusts Medpace Price Target to $270 From $215, Maintains Neutral Rating MT
Guggenheim Raises Medpace Holdings' Price Target to $273 From $252, Keeps Buy Rating MT
Guggenheim Upgrades Medpace Holdings to Buy From Neutral, Price Target is $252 MT
UBS Lowers Price Target on Medpace to $215 From $238, Keeps Neutral Rating MT
UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $238 From $142 MT
Baird Adjusts Medpace Holdings' Price Target to $217 From $200, Keeps Neutral Rating MT
Baird Adjusts Price Target on Medpace Holdings to $200 From $145, Maintains Neutral Rating MT
UBS Initiates Coverage on Medpace Holdings With Sell Rating, $142 Price Target MT
Baird Lowers Price Target for Medpace Holdings to $137 From $151, Maintains Neutral Rating MT
Guggenheim Initiates Coverage on Medpace Holdings With Neutral Rating MT
MEDPACE : Truist Adjusts Price Target on Medpace Holdings to $200 From $193, Maintains Buy Rating MT
MEDPACE : Credit Suisse Adjusts Medpace Holdings' Price Target to $205 from $200, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
390.6 USD
Average target price
423.2 USD
Spread / Average Target
+8.35%
High Price Target
480 USD
Spread / Highest target
+22.90%
Low Price Target
296 USD
Spread / Lowest Target
-24.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Medpace Holdings, Inc.

Baird
Jefferies & Co.
Deutsche Bank Securities
UBS
Guggenheim
Truist Securities
Credit Suisse
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. Consensus Medpace Holdings, Inc.